Health Canada says it's reviewing new safety data on AstraZeneca's heartburn drugs Nexium and Prilosec. The preliminary data shows patients may have had more heart attacks and other cardiac problems than did patients who treated their digestive problems with surgery. The FDA, however, says its review of the data found no increased risk of heart problems. Nexium is AstraZeneca's best-selling drug, with worldwide sales of $1.3 billion during the second quarter of 2007.
- check out this article